Company: DHR
Filing Date: 2025-10-21
Form Type: 10-Q
Source: 0000313616-25-000182
Chunk: 92

Company: DANAHER CORP /DE/
Filing Date: 2025-10-21
Form: 10-Q
Item: Item 8
Chunk 92
---
  The amount of the impairment was primarily attributable to the conclusion that the trade name was no longer indefinite-lived, as well as current lower levels of demand in the genomics market, including at emerging biotechnology customers and at two large customers.  After recognition of the impairment in the second quarter of 2025, the remaining net book value of the trade name was $76 million and will be amortized over the asset’s remaining useful life of eight years.  The Company continues to monitor for any changes to the business performance or key assumptions.  In connection with both trade name impairments mentioned above, the Company also tested the related long-lived asset group and the related reporting unit goodwill for impairment, and in each case the Company identified no impairment. During the third quarter of 2025, the Company identified impairment triggers for certain technology assets, a trade name and other intangible assets in the Biotechnology and Diagnostics segments.  In the three and nine-month periods ended September 26, 2025, the Company recorded impairment charges of $101 million related to these long-lived assets, which is included in selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings.  Additionally, during the nine-month period ended September 26, 2025, the Company recorded a $15 million impairment related to a facility in the Biotechnology segment.The reorganization of the Life Sciences segment resulted in a change to the businesses included in two of the Company’s five reporting units for goodwill beginning at the start of the third quarter of 2025.  The Company used the relative fair value method to reallocate goodwill between the impacted reporting units within the Life Sciences segment.  The Company performed the quantitative goodwill impairment analysis immediately prior to and following the change in the reporting units.  As of the date of the impairment tests, the carrying value of the goodwill included in each individual reporting unit ranged from approximately $1.2 billion to $23.1 billion for both the previous reporting units and for the current reporting units (after the changes within Life Sciences).  No impairments of goodwill were identified in either of the impairment evaluations before or immediately after the change in reporting units.  The factors used by management in its impairment analysis are inherently subject to uncertainty.  If actual results are not consistent with management’s estimates and assumptions, goodwill and other intangible assets may not be recoverable and a charge would need to be taken against net earnings.

The Company will continue to review goodwill and other intangible assets for impairment when events or changes in